Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY26 results · Oct–Dec 2025
Procter & Gamble Health reported revenue from operations of ₹373.86 crore (up 20.7% from Q3 FY25) and net profit of ₹77.59 crore (down 14.6% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a standalone basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 373.86 | 309.77 | +20.7% | 324.92 | +15.1% |
| Other income | 4.36 | 3.96 | +10.1% | 4.95 | −11.9% |
| Total income | 378.22 | 313.73 | +20.6% | 329.87 | +14.7% |
| Profit before tax | 108.82 | 121.69 | −10.6% | 119.02 | −8.6% |
| Net profit for the period | 77.59 | 90.90 | −14.6% | 88.54 | −12.4% |
| EPS, basic (₹) | 46.74 | 54.76 | −14.6% | 53.34 | −12.4% |
| Net margin (%) | 20.8 | 29.3 | 27.2 |
Standalone
- Filed with BSE
- 06 Feb 2026, 17:57 IST
- Board meeting
- 06 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE